Authors' recommendations: AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA326) NICE GUIDANCE ISSUED NOVEMBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Imatinib (Glivec®) is recommended for restricted use within NHS Wales. Imatinib (Glivec®) should be restricted for use in the following subpopulation within its licensed indication for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD117)-positive gastrointestinal stromal tumours. Patients who have low or very low risk of recurrence should not receive adjuvant treatment. Imatinib (Glivec®) should be restricted for use in patients who are considered to be at high risk of relapse according to the Miettinen criteria. Imatinib (Glivec®) is not recommended for use within NHS Wales outside of this subpopulation.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/1653

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC